238 related articles for article (PubMed ID: 28534839)
1. Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.
Zhou Y; Zhang N; Tang S; Qi X; Zhao L; Zhong R; Peng Y
Molecules; 2017 May; 22(5):. PubMed ID: 28534839
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in the Discovery of CK2 Allosteric Inhibitors: From Traditional Screening to Structure-Based Design.
Chen X; Li C; Wang D; Chen Y; Zhang N
Molecules; 2020 Feb; 25(4):. PubMed ID: 32079098
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for low-affinity binding of non-R2 carboxylate-substituted tricyclic quinoline analogs to CK2α: comparative molecular dynamics simulation studies.
Zhou Y; Li X; Zhang N; Zhong R
Chem Biol Drug Des; 2015 Feb; 85(2):189-200. PubMed ID: 24903887
[TBL] [Abstract][Full Text] [Related]
4. An overview about the impact of hinge region towards the anticancer binding affinity of the Ck2 ligands: a quantum chemical analysis.
Deepa P; Thirumeignanam D; Kolandaivel P
J Biomol Struct Dyn; 2019 Sep; 37(15):3859-3876. PubMed ID: 30301411
[TBL] [Abstract][Full Text] [Related]
5. Insights into the Impact of Linker Flexibility and Fragment Ionization on the Design of CK2 Allosteric Inhibitors: Comparative Molecular Dynamics Simulation Studies.
Zhou Y; Zhang N; Qi X; Tang S; Sun G; Zhao L; Zhong R; Peng Y
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301250
[TBL] [Abstract][Full Text] [Related]
6. Identification and Biological Evaluation of CK2 Allosteric Fragments through Structure-Based Virtual Screening.
Li C; Zhang X; Zhang N; Zhou Y; Sun G; Zhao L; Zhong R
Molecules; 2020 Jan; 25(1):. PubMed ID: 31935979
[TBL] [Abstract][Full Text] [Related]
7. Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study.
Wang X; Pan P; Li Y; Li D; Hou T
Mol Biosyst; 2014 May; 10(5):1196-210. PubMed ID: 24647611
[TBL] [Abstract][Full Text] [Related]
8. Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach.
Pardhi T; Vasu K
J Biomol Struct Dyn; 2018 Jan; 36(1):177-194. PubMed ID: 27960601
[TBL] [Abstract][Full Text] [Related]
9. Structural determinants of CX-4945 derivatives as protein kinase CK2 inhibitors: a computational study.
Liu H; Wang X; Wang J; Wang J; Li Y; Yang L; Li G
Int J Mol Sci; 2011; 12(10):7004-21. PubMed ID: 22072932
[TBL] [Abstract][Full Text] [Related]
10. 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site.
Bestgen B; Krimm I; Kufareva I; Kamal AAM; Seetoh WG; Abell C; Hartmann RW; Abagyan R; Cochet C; Le Borgne M; Engel M; Lomberget T
J Med Chem; 2019 Feb; 62(4):1803-1816. PubMed ID: 30689953
[TBL] [Abstract][Full Text] [Related]
11. Structure-based identification of novel CK2 inhibitors with a linear 2-propenone scaffold as anti-cancer agents.
Qi X; Zhang N; Zhao L; Hu L; Cortopassi WA; Jacobson MP; Li X; Zhong R
Biochem Biophys Res Commun; 2019 Apr; 512(2):208-212. PubMed ID: 30878184
[TBL] [Abstract][Full Text] [Related]
12. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
Battistutta R; Cozza G; Pierre F; Papinutto E; Lolli G; Sarno S; O'Brien SE; Siddiqui-Jain A; Haddach M; Anderes K; Ryckman DM; Meggio F; Pinna LA
Biochemistry; 2011 Oct; 50(39):8478-88. PubMed ID: 21870818
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase CK2 in health and disease: Structural bases of protein kinase CK2 inhibition.
Battistutta R
Cell Mol Life Sci; 2009 Jun; 66(11-12):1868-89. PubMed ID: 19387547
[TBL] [Abstract][Full Text] [Related]
14. Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.
Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Anderes K; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Trent K; Rice WG; Ryckman DM
J Med Chem; 2011 Jan; 54(2):635-54. PubMed ID: 21174434
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of CX-4945 binding to human protein kinase CK2.
Ferguson AD; Sheth PR; Basso AD; Paliwal S; Gray K; Fischmann TO; Le HV
FEBS Lett; 2011 Jan; 585(1):104-10. PubMed ID: 21093442
[TBL] [Abstract][Full Text] [Related]
16. Discovery and design of tricyclic scaffolds as protein kinase CK2 (CK2) inhibitors through a combination of shape-based virtual screening and structure-based molecular modification.
Sun H; Xu X; Wu X; Zhang X; Liu F; Jia J; Guo X; Huang J; Jiang Z; Feng T; Chu H; Zhou Y; Zhang S; Liu Z; You Q
J Chem Inf Model; 2013 Aug; 53(8):2093-102. PubMed ID: 23937544
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 5-(3-Chlorophenylamino)benzo[
Wang Y; Lv Z; Chen F; Wang X; Gou S
J Med Chem; 2021 Apr; 64(8):5082-5098. PubMed ID: 33834781
[TBL] [Abstract][Full Text] [Related]
18. Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking.
Di-wu L; Li LL; Wang WJ; Xie HZ; Yang J; Zhang CH; Huang Q; Zhong L; Feng S; Yang SY
J Mol Graph Model; 2012 Jun; 36():42-7. PubMed ID: 22516037
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel CK2 leads by cross-docking based virtual screening.
Sun H; Wu X; Xu X; Jiang Z; Liu Z; You Q
Med Chem; 2014; 10(6):628-39. PubMed ID: 24286395
[TBL] [Abstract][Full Text] [Related]
20. Rational Design of Coumarin Derivatives as CK2 Inhibitors by Improving the Interaction with the Hinge Region.
Zhang N; Chen WJ; Zhou Y; Zhao H; Zhong RG
Mol Inform; 2016 Jan; 35(1):15-8. PubMed ID: 27491649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]